Study of new targeted drug vs chemo for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called Izalontamab Brengitecan (a targeted therapy that delivers chemo straight to cancer cells) against standard platinum chemotherapy for people whose bladder cancer worsened after immunotherapy. It may be an option if you are fit for chemo but haven't had platinum chemo recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has spread or can't be removed by surgery.
- You received an immunotherapy drug (like Keytruda or Tecentriq) for your advanced cancer, but it stopped working.
- You haven't had platinum chemotherapy (like cisplatin or carboplatin) in the last 12 months.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.